Drug intelligence / Profile preview

rCERP

Development stage: Preclinical
Lead developer: Hauul Bio
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

rCERP is a preclinical-stage therapeutic candidate being developed by the South Korean biotechnology company Hauulbio. It is a recombinant protein based on the company's proprietary Cancer-specific Epitope-Revealing Protein (CERP) technology. This platform is designed to identify and target specific epitopes that are uniquely or over-expressed on the surface of cancer cells. While Hauulbio utilizes this technology primarily to support its CAR-T cell therapy platforms (ModCAR and ShotCAR), rCERP is positioned as a distinct pipeline candidate. Specific molecular targets and primary clinical indications for rCERP have not been publicly disclosed, but it is currently undergoing early-stage development for applications in oncology.

Other names: recombinant Cancer-specific Epitope-Revealing Protein

Beyond the preview

Go deeper on rCERP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rCERP.

Explore the full profile